Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents

Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents

Autor Sader, Helio S. Autor UNIFESP Google Scholar
Fritsche, Thomas R. Google Scholar
Jones, Ronald N. Google Scholar
Instituição JMI Labs Inc
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
Resumo One hundred recent clinical Pseudomonas aeruginosa isolates were used to assess the quantitative (MIC) and qualitative (susceptibility category) accuracies of the MicroScan WalkAway, VITEK, and VITEK 2 automated susceptibility test systems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested. Isolates were selected so that the MICs for the isolates over-represented the MICs near the breakpoints to assess precisely the agreement between the results obtained with the automated systems and the results obtained by the reference tests. the categorical and MIC results from the automated systems were compared to the consensus result of three reference methods: broth microdilution, agar dilution, and disk diffusion. the consensus categorical testing (susceptibility and resistance) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin-tazobactam. All systems tested exhibited a high, unacceptable level of very major (false-susceptible) errors for piperacillin-tazobactam (19 to 27%). Major (false-resistant) error rates were generally acceptable (0 to 3%), but minor error rates were elevated (8 to 32%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent trends toward false resistance. Manufacturer reevaluation of these automated systems for the testing of selected beta-lactams with current clinical isolates of P. aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors.
Idioma Inglês
Data de publicação 2006-03-01
Publicado em Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 44, n. 3, p. 1101-1104, 2006.
ISSN 0095-1137 (Sherpa/Romeo, fator de impacto)
Publicador Amer Soc Microbiology
Extensão 1101-1104
Fonte http://dx.doi.org/10.1128/JCM.44.3.1101-1104.2006
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000236095000066
Endereço permanente http://repositorio.unifesp.br/handle/11600/28758

Exibir registro completo




Arquivo

Nome: WOS000236095000066.pdf
Tamanho: 55.67KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta